Abaloparatide Overview, Dosing & Safety | Peptide Database

Abaloparatide (Tymlos)

PTHrP Analog | Anabolic Bone-Building Agent

Community Research

Join others researching Abaloparatide — share findings, ask questions, and learn from real experiences

Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.

Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.

Molecular Data

Complex or non-standard sequence format

Research Indications

FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies.

FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments.

Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures.

ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.

Dosing Protocols

Abaloparatide is administered as a once-daily subcutaneous injection in the periumbilical (around the navel) region of the abdomen. It comes in pre-filled pen devices (Tymlos). Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies. A transdermal patch formulation is also in development.

Osteoporosis treatment

80 mcg

Once daily

SubQ (periumbilical abdomen)

Reconstitution Instructions

Pre-filled pen device (Tymlos)

Pen needles

Alcohol swabs

1 Store pen refrigerated at 2-8°C (do not freeze)

2 Allow to reach room temperature before injection

3 Attach new needle for each injection

4 Inject subcutaneously in periumbilical region

5 Rotate injection sites

6 Discard pen after 30 days even if medication remains

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Hypercalciuria (high calcium in urine)

Dizziness

Nausea

Headache

Palpitations

Fatigue

Upper abdominal pain

Vertigo

Injection site reactions

Stop Signs - Discontinue if:

Signs of hypercalcemia (confusion, fatigue, excessive thirst)

Persistent bone pain

Severe dizziness or fainting

Allergic reactions

Contraindications

Paget's disease of bone

Prior external beam or implant radiation therapy to skeleton

Bone metastases or history of skeletal malignancies

Metabolic bone diseases other than osteoporosis

Pre-existing hypercalcemia

Pregnancy or nursing

Cumulative use exceeding 2 years lifetime

Quality Checklist

Good Signs

Clear, colorless solution

Pharmaceutical grade (Tymlos/Eladynos)

Proper cold chain maintained

Intact pen device

Within expiration date

Warning Signs

Research-grade products lack FDA oversight

Temperature excursions may affect potency

Bad Signs

Cloudy or discolored solution

Particulates visible

Exposed to freezing or high temperatures

Damaged pen device

Frequently Asked Questions

Why is abaloparatide limited to 2 years of use?

Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies at very high doses. This is a precautionary measure based on animal data, and the ACTIVExtend trial demonstrated that benefits can be maintained by transitioning to alendronate after 18 months of abaloparatide.

Is abaloparatide better than teriparatide (Forteo)?

Yes. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It also carries lower hypercalcemia risk than teriparatide despite more potent bone-building activity.

What causes the dizziness and palpitations reported with abaloparatide?

Dizziness, palpitations, and vertigo occur in a subset of users, likely due to transient hypotension or hemodynamic changes from rapid PTH receptor activation. These effects typically subside with continued use as the body adapts. Orthostatic hypotension is a rare but serious warning sign requiring discontinuation.

Can women take abaloparatide if they're still in their reproductive years?

No. Abaloparatide is teratogenic and contraindicated in pregnancy or potential pregnancy. It's FDA-approved specifically for postmenopausal women and men with osteoporosis, making it appropriate for women beyond reproductive years.

References

Abaloparatide showed substantial reduction in vertebral fractures and greater BMD increases at spine, hip, and femur compared to placebo and teriparatide.

18 months abaloparatide followed by alendronate significantly reduced vertebral and nonvertebral fractures.

Significant BMD increases at 40 and 80 mcg doses; abaloparatide showed superior anabolic effects on hips vs teriparatide.

Abaloparatide preferentially binds RG conformational state of PTH1R, producing more anabolic bone effects.

Related Peptides

Different mechanisms; no known interactions.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.